Detection of immunological biomarkers correlated with asthma control and quality of life measurements in sera from chronic asthmatic patients

Division of Pediatric Allergy and Immunology, Mount Sinai School of Medicine, New York, New York 10029-6574, USA.
Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology (Impact Factor: 2.75). 03/2011; 106(3):205-13. DOI: 10.1016/j.anai.2010.11.019
Source: PubMed

ABSTRACT Clinical outcomes of patients with asthma are highly variable. Immunological biomarkers associated with asthma control have not been elucidated.
To identify the association between clinical control of asthma and serum immunological profiles of asthmatics and compare these profiles with those of healthy controls by using a multiplex assay.
Sera were obtained from 28 nonsmokers 18 to 55 years of age with moderate and severe persistent asthma. Patients were classified as having well-controlled (WC, n = 14) or poorly controlled (PC, n = 14) asthma based on their responses to the Asthma Control Questionnaire and Asthma Quality of Life Questionnaire. Sera from nonasthmatic control individuals (NAC, n = 14) were used for comparison. Levels of 50 analytes, including cytokines, chemokines, angiogenic, and growth factors, were determined, using a multiplex assay.
Twelve of the 29 cytokines levels were significantly higher in patients with asthma than in NACs, but only interferon gamma levels were significantly lower in patients with asthma than in the NAC group. Among these, interleukin (IL)-3 and IL-18 levels were significantly higher in the PC group than the WC group. Five of the 12 tested chemokine levels were significantly higher in patients with asthma than in NACs. Five of six growth factor levels were significantly higher in patients with asthma than in NACs, and 3 were higher in PC than WC. Interleukin-18, fibroblast growth factor, hepatocyte growth factor, and stem cell growth factor-beta were positively correlated with poor asthma control and negatively with quality of life scores.
Increased serum levels of fibroblast growth factor, hepatocyte growth factor, and stem cell growth factor-beta might be useful biomarkers of asthma control status and targets of future asthma therapy.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Human airways contact with pathogen-associated molecular patterns and danger-associated molecular patterns present in many environments. Asthmatic's airways may be more susceptible to these patterns and lead to inflammasome activation; however, the participation of inflammasome in the development and exacerbation of asthma is not fully understood and remains controversial. Asthma is a heterogeneous group composed of different airway inflammation patterns with different underlying immune mechanisms. One mechanism is neutrophilic airway inflammation based on the axis of inflammasome activation, interleukin (IL) 1β/IL-18 production, T helper 17 activation, IL-8/IL-6 overproduction, and neutrophilic inflammation. The role of inflammasome activation has been highlighted in experimental asthma models and some evidence of inflammasome activation has been recently demonstrated in human neutrophilic asthmatic airways. In addition to caspase-1 activation, proteinase 3 and other protease from activated neutrophils directly cleave pro-IL-1β and pro-IL-18 to IL-1β and IL-18, which contribute to the phenotype of subsequent adaptive immune responses without inflammasome activation. Data suggests that neutrophilics in asthmatic airways may have an additional effect in initiating inflammasome activation and amplifying immune responses. Among the mediators from neutrophils, S100A9 seems to be one candidate mediator to explain the action of neutrophils in amplifying the airway inflammation in concert with inflammasome.
    10/2014; 4(4):187-96. DOI:10.5415/apallergy.2014.4.4.187
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: All of life is regulated by complex and organized chemical reactions that help dictate when to grow, to move, to reproduce, and to die. When these processes go awry, or are interrupted by pathological agents, diseases such as cancer, autoimmunity, or infections can result. Cytokines, chemokines, growth factors, adipokines, and other chemical moieties make up a vast subset of these chemical reactions that are altered in disease states, and monitoring changes in these molecules could provide for the identification of disease biomarkers. From the first identification of carcinoembryonic antigen, to the discovery of prostate-specific antigen, to numerous others described within, biomarkers of disease are detectable in a plethora of sample types. The growing number of biomarkers for infection, autoimmunity, and cancer allow for increasingly early detection, to identification of novel drug targets, to prognostic indicators of disease outcome. However, more and more studies are finding that a single cytokine or growth factor is insufficient as a true disease biomarker and that a more global perspective is needed to understand true disease biology. Such a broad view requires a multiplexed platform for chemical detection, and antibody arrays meet and exceed this need by performing this detection in a high-throughput fashion. Herein, we will discuss how antibody arrays have evolved, and how they have helped direct new drug target design, helped identify therapeutic disease markers, and helped in earlier disease detection. From asthma to renal disease, and neurological dysfunction to immunologic disorders, antibody arrays afford a bright future for new biomarker discovery.
    Advances in clinical chemistry 02/2015; DOI:10.1016/bs.acc.2015.01.002 · 4.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This review informs on current literature on patents for biomarkers for asthma from 2009 to 2011. Variable airflow obstruction in asthma is generally triggered by gene-environment interactions that can lead to key symptoms of cough, shortness of breath, chest tightness, and wheezing. The episodic and variable degrees of airway hyperresponsiveness arise from a variety of inflammatory pathways that can make diagnosis and management difficult. Standard pulmonary function tests used for the diagnosis of asthma may fail to predict individual responses to the standard bronchodilator and corticosteroid therapies. Phenotypic predispositions can alter the severity of the asthmatic condition and treatment response. Biomarkers from sputum, exhaled gases, exhaled breath condensates, urine, serum, and broncheolaveolar fluid lavage proteins are currently explored to provide objective metrics for identifying individuals at risk, provide therapy guidance, monitor disease progression and evaluate response to therapy, as a supplement to standard pulmonary function tests. Updates on the refinement of technologies, inherent limitations and benefits of these biomarkers are discussed to provide insights on how current understanding of pathologic mechanisms has been applied to provide information for addressing gaps in the diagnosis and management of asthma.
    01/2012; 2(1):54-59. DOI:10.2174/2210309011202010054